Mural Health wants to pay you fairly for being a test subject.

A company built on a slightly awkward premise

Here is a fact that should, by all rights, make a business textbook uncomfortable. In 2008, a man named Sam Whitaker invented the ClinCard - the prepaid card that became the default way clinical trials pay the people who participate in them. He built that idea into Greenphire, a company that reportedly crossed a billion-dollar valuation on roughly $2.2 million of outside money, which is the kind of capital efficiency that makes venture investors weep softly into their term sheets.

Then, in 2022, Whitaker started a new company - Mural Health - and pointed it directly at the thing he had built. Mural Health's own materials describe its platform as "both a disruption to Sam's original platform and an expansion of functionality." Translated out of press-release, that means: the guy who made the card is now selling the tool designed to make the card look old. It is unusual to compete against your own greatest hit. Most founders frame the plaque and move to the beach. Whitaker apparently decided the plaque was a to-do list.

The premise is worth sitting with, because it explains everything else. Clinical trials have a churn problem that nobody in the room has an incentive to say out loud. Participants drop out - not usually because the science fails, but because the experience does. Payments arrive late. Prepaid cards quietly skim balances through inactivity fees. A visit to a study site can mean a two-hour bus ride for a twenty-minute appointment, paid for out of pocket by someone who is, let us remember, sick enough to be in a trial. Every one of those participants who quits is a hole in the data and a cost to the sponsor. Mural Health's entire thesis is that these are not three separate annoyances. They are one experience, and if you fix the experience, you keep the patient.

Mural Link, or: everything the participant touches, in one place

The company's flagship is called Mural Link, and Mural Health bills it as the clinical research industry's first participant management platform. That phrase does a lot of quiet work. "Participant management" is the admission that a trial participant is, functionally, a customer - someone whose ongoing satisfaction is a thing that can be won or lost. Software has managed sponsors' data and sites' logistics for years. Managing the human at the center of it is the newer idea. Here is what lives inside the box.

The genuinely clever part is the direction of the design. Mural Health built for the participant first - the person with the least institutional power - and then discovered that happier participants make for happier sites, and happier sites make for happier sponsors. It is design down the org chart rather than up it. The sponsor, who actually writes the check, benefits last and most, which is a satisfying bit of engineering if you think about it for a second.

Three people, one very experienced hunch

Mural Health was founded in 2022 by Sam Whitaker, Jason Dong, and Shawn Milochik. Whitaker, the co-founder and co-CEO, is the one carrying the ClinCard history, and it matters more than the usual founder résumé line. In an industry as regulated and relationship-driven as clinical research, credibility compounds - and Whitaker spent more than a decade earning it before this company existed. When you have already built the category once, you know exactly which mistakes not to repeat. That is not a nice-to-have in healthtech. It is most of the moat.

$8M from Bessemer, and what it actually bought

In September 2023, Mural Health announced an $8 million seed round led by Bessemer Venture Partners, with Virtue VC, Operator Partners, Arkitect Ventures, Correlation Ventures, and Project Mayhem Ventures along for the ride. Total funding to date runs to roughly $20.7 million. What Bessemer was really underwriting, you suspect, was less a slide deck than a track record - a founder who had already made the expensive mistakes on someone else's dime.

How it unfolded

Allies, rivals, and the ghost of the ClinCard

Mural Health has been busy stitching alliances: ProofPilot for decentralized-trial payment flows, Clinflash to reach trials in China and beyond, the Society for Clinical Research Sites (via its Global Impact Partner Program) to stay close to the sites themselves, and Uber and Lyft to make the transportation piece real rather than aspirational. The competitive set is the rest of the participant-payment and decentralized-trial world - Medable, Suvoda, Curebase, Paradigm, and, yes, Greenphire's own ClinCard, the incumbent Whitaker is now running against. Competing with your own legacy product is a strange kind of full circle, but it does mean the challenger knows precisely where the bodies are buried.

If you are a …

Interviews, demos, and the paper trail

The official channels